Evidence map›Paper›PMID 33791022›Full record

ArticleExperimental and therapeutic medicine2021

Association of antipsychotic use with raised eosinophil count.

Konstantinos Tsamakis, Christoph Mueller, Ioannis Hortis, Maria Kallergi, Ioannis Tolos, Evangelos Alevyzakis, Nikolaos Siafakas, Andreas Ouranidis, Dimitrios Tsiptsios, Stylianos Kympouropoulos and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

Konstantinos TsamakisSecond Department of Psychiatry, University General Hospital 'Attikon', National and Kapodistrian University of Athens, Athens 12462, Greece.
Christoph MuellerInstitute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.
Ioannis HortisSecond Department of Psychiatry, University General Hospital 'Attikon', National and Kapodistrian University of Athens, Athens 12462, Greece.
Maria KallergiDepartment of Biomedical Engineering, University of West Attica, Campus I, Athens 12243, Greece.
Ioannis TolosSecond Department of Psychiatry, University General Hospital 'Attikon', National and Kapodistrian University of Athens, Athens 12462, Greece.
Evangelos AlevyzakisSecond Department of Psychiatry, University General Hospital 'Attikon', National and Kapodistrian University of Athens, Athens 12462, Greece.
Nikolaos SiafakasSecond Laboratory of Microbiology, University General Hospital 'ATTIKON', National and Kapodistrian University of Athens, Medical School, Athens 12462, Greece.
Andreas OuranidisDepartment of Pharmaceutical Technology, School of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki 54636, Greece.
Dimitrios TsiptsiosDepartment of Neurophysiology, South Tyneside and Sunderland NHS Foundation Trust, Sunderland SR47TP, UK.
Stylianos KympouropoulosSecond Department of Psychiatry, University General Hospital 'Attikon', National and Kapodistrian University of Athens, Athens 12462, Greece.
Demetrios A SpandidosLaboratory of Clinical Virology, School of Medicine, University of Crete, Heraklion 71003, Greece.
Nikolaos SmyrnisSecond Department of Psychiatry, University General Hospital 'Attikon', National and Kapodistrian University of Athens, Athens 12462, Greece.
Emmanouil RizosSecond Department of Psychiatry, University General Hospital 'Attikon', National and Kapodistrian University of Athens, Athens 12462, Greece.
National and Kapodistrian University of Athens · GRUniversity General Hospital Attikon · GRAristotle University of Thessaloniki · GRKing's College London · GBSouth Tyneside and Sunderland NHS Foundation Trust · GBUniversity of Crete · GRUniversity of West Attica · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current study aimed to assess the possibility of an association between first and second generation antipsychotic medication and raised eosinophil count. A total of 22 in-patients at the psychiatric unit of the University General Hospital 'Attikon', a tertiary hospital, were included in the present study. Patients had received antipsychotic monotherapy and did not have any co-morbidities or require additional treatments. Patients were monitored weekly and their eosinophil count was assessed. One-way ANOVA and summary measures analysis were applied to study the effect of time and medication type on the absolute eosinophil concentration (or relative percentage) for each patient. The differences in mean eosinophil concentrations or relative percentage by patient and time were also assessed. An increase in the absolute concentration and the relative percentage of eosinophils over time was observed in patients receiving Olanzapine, Haloperidol and Aripiprazole. However, there was no difference between individual medications. In conclusion, antipsychotics may be associated with increased eosinophil count over time; however, larger studies involving more patients and a longer follow-up are required to reach a definitive conclusion.

Indexed as

antipsychoticsaripiprazoleeosinophil countfirst and second generationhaloperidolmonotherapyolanzapine

Identifiers

PMID33791022
PMCPMC8005733
OpenAlexW3138542514

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.